SAFETY AND TOLERABILITY OF EXTENDED (96 WEEKS) TREATMENT WITH PEGINTERFERON ALFA-2A [40KD] IN GENOTYPE D PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B

被引：0
|
作者：
Lampertico, Pietro [1 ]
Vigano, Mauro [1 ]
Di Costanzo, Giovan Giuseppe [2 ]
Sagnelli, Evangelista [3 ]
Fasano, Massimo [4 ]
Di Marco, Vito [5 ]
Boninsegna, Sara [6 ]
Farci, Patrizia [7 ]
Fargion, Silvia [8 ]
Giuberti, Tiziana [9 ]
Iannacone, Claudio [10 ]
Massetto, Benedetta [11 ]
Martins, Eduardo B. [12 ]
Colombo, Massimo [1 ]
机构：
[1] Univ Milan, Div Gastroenterol 1, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Milan, Italy
[2] Cardarelli Hosp, Liver Unit, Naples, Italy
[3] SS Anna & Sebastiano Hosp, Infect Dis Unit, Caserta, Italy
[4] Univ Bari, Clin Infect Dis, Bari, Italy
[5] Univ Palermo, Gastroenterol & Hepatol Unit, Di Bi MIS, Palermo, Italy
[6] Univ Padua, Dept Surg & Gastroenterol Sci, Padua, Italy
[7] Univ Cagliari, Dept Med Sci, Monserrato, Italy
[8] Univ Milan, Dept Internal Med, IRCCS Fdn Policlin, Milan, Italy
[9] Azienda Osped Univ Parma, Unit Infect Dis & Hepatol, Parma, Italy
[10] SPARC Consulting, Milan, Italy
[11] Roche, Monza, Italy
[12] Genentech Inc, San Francisco, CA 94080 USA
来源：
HEPATOLOGY | 2010年 / 52卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
135
引用
收藏
页码：387A / 387A
页数：1
相关论文
共 50 条
  • [31] Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B
    Lampertico, Pietro
    Vigano, Mauro
    Di Costanzo, Giovan Giuseppe
    Sagnelli, Evangelista
    Fasano, Massimo
    Di Marco, Vito
    Boninsegna, Sara
    Farci, Patrizia
    Fargion, Silvia
    Giuberti, Tiziana
    Iannacone, Claudio
    Regep, Loredana
    Massetto, Benedetta
    Facchetti, Floriana
    Colombo, Massimo
    GUT, 2013, 62 (02) : 290 - 298
  • [32] Efficacy and tolerability of peginterferon alfa-2a (40kd) and ribavirin in genotype 4 patients with chronic hepatitis C (CHC) under real life conditions
    Zehnter, E.
    Mauss, S.
    Kaiser, S.
    Boeker, K.
    Lutz, T.
    Heyne, R.
    John, C.
    Moog, G.
    Schober, A.
    Pfaff, R.
    Zipf, A.
    Racky, S.
    Lohmeyer, J.
    Bokemeyer, B.
    Kallinowski, B.
    Witthoeft, T.
    Alshuth, U.
    Hueppe, D.
    JOURNAL OF HEPATOLOGY, 2008, 48 : S316 - S316
  • [33] PREDICTORS OF DEVELOPMENT OF HBEAG-NEGATIVE CHRONIC HEPATITIS B FOLLOWING PEGINTERFERON ALFA-2A THERAPY IN HBEAG-POSITIVE CHRONIC HEPATITIS B
    Peng, Cheng-Yuan
    Shih, Chao-Jen
    Lo, Pei-Shuan
    Huang, Chia-Lin
    Lai, Hsueh-Chou
    Su, Wen-Pang
    Chuang, Po-Heng
    Kao, Jung-Ta
    HEPATOLOGY, 2011, 54 : 1027A - 1028A
  • [34] HBSAG LEVELS DECLINE DURING PEGINTERFERON ALFA-2A [40KD] (PEGASYS) TREATMENT IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B FAVORS 6 MONTHS POST-TREATMENT RESPONSE: PERSEAS COHORT INTERIM ANALYSIS
    Goulis, I.
    Akriviadis, E.
    Karatapanis, S.
    Deutsch, M.
    Dalekos, G.
    Raptopoulou-Gigi, M.
    Mimidis, K.
    Germanidis, G.
    Triantos, C.
    Drakoulis, C.
    Chounta, A.
    Tsoplou, F.
    Zintzaras, E.
    Bakalos, G.
    Papatheodoridis, G.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S201 - S202
  • [35] PREDICTIVE FACTORS OF THROMBOCYTOPENIA IN TREATMENT OF CHRONIC HEPATITIS C (CHC) PATIENTS WITH PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN
    Mauss, S.
    Schober, A.
    Lutz, T.
    Moog, G.
    Schuchmann, M.
    Heyne, R.
    John, C.
    Schiffelholz, W.
    Baumgarten, A.
    Hey, K. -H.
    Eisenbach, C.
    Teuber, G.
    Schmidt, W.
    Bruch, H. -R.
    Geyer, P.
    Alshuth, U.
    Hueppe, D.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S185 - S185
  • [36] Predictive Factors of Thrombocytopenia in Treatment of Chronic Hepatitis C (CHC) Patients With Peginterferon Alfa-2a (40KD) and Ribavirin
    Mauss, Stefan
    Schober, Andreas
    Lutz, Thomas
    Moog, Gero
    Schuchmann, Marcus
    Heyne, Renate
    John, Christine
    Schiffelholz, Willibold
    Baumgarten, Axel
    Hey, Karl-Heinz
    Eisenbach, Christoph
    Teuber, Gerlinde
    Schmidt, Wolfgang
    Bruch, Harald-Robert
    Geyer, Peter
    Alshuth, Ulrich
    Hueppe, Dietrich
    GASTROENTEROLOGY, 2011, 140 (05) : S948 - S948
  • [37] Peginterferion alfa-2a (40KD) (Pegasys®) for the treatment of patients with chronic hepatitis C
    Ferenci, P
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2003, 57 (07) : 610 - 615
  • [38] Cost-effectiveness of peginterferon alfa-2a (40KD) compared to lamivudine for the treatment of E antigen negative chronic hepatitis B in the UK
    Veenstra, DL
    Sullivan, SD
    Lewis, G
    Green, J
    VALUE IN HEALTH, 2005, 8 (03) : 371 - 371
  • [39] Outcome of treatment with peginterferon alfa-2a (40KD) in HBeAg-positive and HBeAg-negative patients with chronic hepatitis B (CHB) in the real-world: interim analysis of data from the large European S-Collate cohort
    Marcellin, Patrick
    Curescu, Manuela G.
    Piekarska, Anna
    Mazur, Wlodzimierz W.
    Hezode, Christophe
    Guyader, Dominique
    Jochum, Christoph
    Foster, Graham R.
    Ouzan, Denis
    Cornberg, Markus
    Bogdan, Manfred
    Messinger, Diethelm
    Cartier, Veronique
    Petersen, Joerg
    HEPATOLOGY, 2013, 58 : 656A - 657A
  • [40] EFFICACY OF PEGINTERFERON ALFA-2A OR ALFA-2B IN TREATMENT OF HBEAG NEGATIVE CHRONIC HEPATITIS B INFECTION
    Karabay, Oguz
    Tuna, Nazan
    Esen, Saban
    HEPATOLOGY, 2011, 54 : 1061A - 1061A
12345